At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Placebo +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution in Healthy Male Volunteers q.d. or b.i.d.for 14 Days (a Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)
In Brief
A Phase 1 clinical trial evaluating Placebo, BI 1015550, and 1 other intervention for Healthy. Completed, enrolled 24 participants across 1 site.
Detailed Summary
To investigate safety, tolerability, and pharmacokinetics of multiple rising oral doses of BI 1015550 in healthy male volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedApr 2013
Primary CompletionJun 2013
TodayJul 2026
First PostedApr 19, 2013
Enrollment StartApr 1, 2013
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.2 years ago
Interventions
Placebodrug
Placebo to BI 1015550
BI 1015550drug
medium dose 1 powder for oral solution
BI 1015550drug
medium dose 2 powder for oral solution
BI1015550drug
low dose 2 powder for oral solution
BI 1015550drug
low dose 1 powder for oral solution